DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Duoneb (Albuterol Sulfate / Ipratropium Bromide) - Summary

 
 



DUONEB SUMMARY

The active components in DuoNeb are albuterol sulfate and ipratropium bromide.

DuoNeb is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator.


See all Duoneb indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Duoneb (Albuterol / Ipratropium)

COPD (Chronic Obstructive Pulmonary Disease)
Source: MedicineNet Alpha 1 Antitrypsin Deficiency Specialty [2014.03.18]
Title: COPD (Chronic Obstructive Pulmonary Disease)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 3/18/2014 7:18:35 PM

COPD Foods Pictures Slideshow: Energy-Boosting Foods for Chronic Obstructive Pulmonary Disease
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2013.11.20]
Title: COPD Foods Pictures Slideshow: Energy-Boosting Foods for Chronic Obstructive Pulmonary Disease
Category: Slideshows
Created: 6/18/2010 12:20:00 PM
Last Editorial Review: 11/20/2013 12:00:00 AM

COPD (Chronic Obstructive Pulmonary Disease) Quiz
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2012.11.06]
Title: COPD (Chronic Obstructive Pulmonary Disease) Quiz
Category: MedicineNet Quiz
Created: 10/8/2012 5:18:00 PM
Last Editorial Review: 11/6/2012 5:24:02 PM

A new once-daily dual bronchodilator treatment for COPD now available in England
Source: Respiratory / Asthma News From Medical News Today [2014.09.23]
GlaxoSmithKline and Theravance, Inc. announce that Anoro® Ellipta®, a new once-daily dual bronchodilator treatment for chronic obstructive pulmonary disease (COPD), is now available via GP...

Combination therapy for COPD associated with better outcomes
Source: Respiratory / Asthma News From Medical News Today [2014.09.16]
Among older adults with chronic obstructive pulmonary disease (COPD), particularly those with asthma, newly prescribed long-acting beta-agonists (LABAs) and inhaled corticosteroid combination...

more news >>

Published Studies Related to Duoneb (Albuterol / Ipratropium)

Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. [2005.07]
Our study compared levalbuterol (LEV) to the combination of racemic albuterol (RAC) and ipratropium bromide (IB) in 140 patients aged 6-18 years presenting to a tertiary hospital Emergency Department with acute asthma and a peak expired flow rate (PEF)<80% predicted.In a sample of children with acute asthma and initial mean PEF<50% predicted, LEV was associated with less tachycardia but had no other advantage over RAC combined with IB.

The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. [2005.05]
BACKGROUND: The pathology of chronic obstructive pulmonary disease (COPD) includes both obstructive and inflammatory components. OBJECTIVE: The aim of this study was to confirm the findings of a previous study that compared the efficacy of a combination of 2 short-acting bronchodilators with the use of an inhaled corticosteroid and a long-acting beta-agonist in the treatment of COPD... CONCLUSION: In this 8-week study, subjects with moderate to severe COPD experienced greater improvements in lung function and symptom measures with FSC than with IB/ALB.

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. [2004.10.23]
BACKGROUND: The issue of whether regular use of an inhaled beta2-adrenergic agonist worsens airflow and clinical outcomes in asthma is controversial. Retrospective studies have suggested that adverse effects occur in patients with a genetic polymorphism that results in homozygosity for arginine (Arg/Arg), rather than glycine (Gly/Gly), at aminoacid residue 16 of the beta2-adrenergic receptor. However, the existence of any genotype-dependent difference has not been tested in a prospective clinical trial... INTERPRETATION: Genotype at the 16th aminoacid residue of the beta2-adrenergic receptor affects the long-term response to albuterol use. Bronchodilator treatments avoiding albuterol may be appropriate for patients with the Arg/Arg genotype.

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. [2004]
BACKGROUND: This is the first comparison of two combination therapies, fluticasone propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of patients with COPD... CONCLUSIONS: Short-term treatment with the combined inhaled corticosteroid and long-acting beta(2)-adrenoceptor agonist fluticasone propionate/salmeterol resulted in greater control of lung function and symptoms than combined ipratropium bromide/albuterol bronchodilator therapy, in patients with COPD.

An evaluation of nebulized levalbuterol in stable COPD. [2003.09]
BACKGROUND: Levalbuterol, the R-isomer of albuterol, has advantages over racemic albuterol in asthma; however, the effectiveness of this beta-agonist in COPD has received little attention. OBJECTIVES: To evaluate the effectiveness of a single dose of nebulized levalbuterol in COPD. DESIGN: A randomized, double-blind, placebo-controlled trial comparing nebulized levalbuterol to racemic albuterol, combined racemic albuterol and ipratropium, and placebo. PATIENTS: Thirty patients with stable COPD (FEV(1) between 45% and 70% of predicted) were studied... CONCLUSION: For single-dose, as-needed use in COPD, there appears to be no advantage in using levalbuterol over conventional nebulized bronchodilators.

more studies >>

Clinical Trials Related to Duoneb (Albuterol / Ipratropium)

Respimat Combivent Trial in COPD [Completed]
The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat? inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat? inhaler (20 mcg), and COMBIVENT? MDI administered q. i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat? to COMBIVENT? MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat? to Atrovent Respimat? monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat? to Atrovent Respimat? monotherapy in FEV1 AUC from 4 to 6 hours will b e analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma [Recruiting]
The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma. In the first cross-over part of the study (Treatment Phases 1 and 2) the marketed product, COMBIVENT CFC MDI will be used. In the second, parallel group part of the trial (Treatment Phase 3) COMBIVENT RESPIMAT will be tested for acute bronchodilator efficacy in a blinded manner at the clinic visits. During the third 4-week treatment phase open label COMBIVENT RESPIMAT will be used for symptom relief as needed.

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent? Inhalation Aerosol in COPD Patients. [Completed]
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler? 18 mcg daily compared to Combivent? MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently prescribed Combivent? MDI.

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma [Completed]

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent? Inhalation Aerosol in COPD Patients. [Completed]
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler? 18 mcg daily compared to Combivent? MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently prescribed Combivent? MDI.

more trials >>

Reports of Suspected Duoneb (Albuterol / Ipratropium) Side Effects

Drug Ineffective (2)Urticaria (2)Chronic Obstructive Pulmonary Disease (2)Tremor (2)Contusion (1)Wrong Drug Administered (1)Oropharyngeal Pain (1)Rash Pruritic (1)Medication Error (1)Dizziness (1)more >>


Page last updated: 2014-09-23

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014